RNAssist and Fiocruz collaborate on TheraPHIX™ project in Brazil

Andrew Goldsborough - our CEO, recently visited Rio de Janeiro, Brazil, to meet with the team at Fiocruz / Bio-Manguinhos as part of a joint project focused on TheraPHIX™, RNAssist’s RNA stabilisation platform designed to improve the durability and accessibility of mRNA-LNP vaccines.

TheraPHIX™ is a proprietary liquid formulation buffer that protects and stabilises RNA at ambient temperatures, enabling longer shelf life and simplified handling without the need for deep-freeze logistics. This technology is designed to make RNA-based vaccines and therapeutics more practical for large-scale use, especially in regions where cold-chain infrastructure is limited.

You can learn more about the technology at vaccines.rnassist.com.

Working with Fiocruz and Bio-Manguinhos represents an important step in expanding the potential of RNA technologies to reach more regions and applications worldwide.